international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug
, e.g., supermarket, food and restaurants (only for takeaway), drug stores. Online sales continued to grow remarkably by 150.0% YoY. Gross profit margin from sale of goods improved outstandingly to
Constructions (2) Registration of 100 drugs formulas (54 formulas for human medicine and 46 formulas for animals) owned by the seller (3) Registration of special drug formulas, consisting of 12 formulas including
persons ) and related services i.e. registration with Food and Drug Administration (FDA), trademark permission, product and packaging design, and brand building etc. to customers who are business operator
transferred on share sale and purchase date from the seller’s connected persons ) and related services i.e. registration with Food and Drug Administration (FDA), trademark permission, product and packaging
. registration with Food and Drug Administration (FDA), trademark permission, product and packaging design, and brand building etc. to customers who are business operator in skin cares and cosmetics. In addition
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
baht or 6. 56 percent from the previous year, mainly due to a decrease of drug and medical supply cost since the volume of general patients and social security patients decreased. Besides, the Company
purpose of use of proceeds 5. Expansion of production capacity for dietary supplement products, introduction of new product packages, and warehouse building (existing business as disclosed in the
financial institutions 50 50 50 - 2018 4. Working capital for business operations 637.24 637.24 368.34 - 2018-2020 Newly – approved of purpose of use of proceeds 5. Expansion of production capacity for